IDXX

Westbrook, Maine-based IDEXX Laboratories, Inc. (IDXX) develops, manufactures, and distributes products for the companion animal veterinary, livestock, poultry, dairy, and water testing markets. Valued at $44.6 billion by market cap, the company also operates an international network of veterinary reference laboratories. The global leader in pet healthcare innovation is expected to announce its fiscal second-quarter earnings for 2026 before the market opens on Tuesday, Aug. 4. Ahead of the event, analysts expect IDXX to report a profit of $3.95 per share on a diluted basis, up 8.8% from $3.63 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports. Dear Google Stock Fans, Mark Your Calendars for July 13 Taiwan Just Waved a Red Flag for Nvidia Stock Taiwan Semi Stock Is Approaching Fair Value Ahead of July 16. How to Play TSM Here. Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. For the full year, analysts expect IDXX to report EPS of $14.68, up 12.2% from $13.08 in fiscal 2025. Its EPS is expected to rise 12.6% year over year to $16.53 in fiscal 2027. IDXX stock has underperformed the S&P 500 Index’s ($SPX) 20.6% gains over the past 52 weeks, with shares up 4.2% during this period. Similarly, it underperformed the State Street Health Care Select Sector SPDR ETF’s (XLV) 18% returns over the same time frame. IDXX underperformed as investors were worried about slowing companion animal growth and weaker demand following the pandemic boom. At the same time, FX headwinds and uneven international demand added pressure to revenue. Analysts’ consensus opinion on IDXX stock is reasonably bullish, with a “Moderate Buy” rating overall. Out of 15 analysts covering the stock, eight advise a “Strong Buy” rating, one suggests a “Moderate Buy,” and six give a “Hold.” IDXX’s average analyst price target is $720.86, indicating a potential upside of 27.9% from the current levels. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com

WESTBROOK, Maine, July 01, 2026--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 second quarter financial results for Tuesday, August 4, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q2 2026 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen to the live conference call, please dial 1-800-330-6730 or 1-213-279-1575 and reference passcode 922025. 2026 Investor Day IDEXX Laboratories, Inc. will host its 2026 Investor Day on Thursday, August 13, 2026, at its corporate headquarters in Westbrook, Maine from 8:00 am to approximately 12:00 pm ET. A live webcast of the presentations will be available on www.idexx.com/investors. Advance registration for the in-person event is required; institutional investors and analysts interested in attending should contact [email protected]. Additional information on IDEXX’s Investor Day will be provided closer to the date of the event. About IDEXX Laboratories, Inc. IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit www.idexx.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260701341726/en/ Contacts Investor Relationsinvestorrelations@id...

A month has gone by since the last earnings report for Idexx Laboratories (IDXX). Shares have lost about 3.2% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Idexx due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important catalysts. IDEXX Laboratories, Inc. (IDXX) posted first-quarter 2026 earnings per share (EPS) of $3.47, up 17.2% year over year. The figure surpassed the Zacks Consensus Estimate by 1.5%. Comparable constant-currency EPS of $3.30 improved 15% year over year. Quarterly revenues increased 14% year over year (up 11% organically) to $1.14 billion. The reported figure topped the Zacks Consensus Estimate by 2.1%. IDEXX derives revenues from four operating segments: CAG, Water, Livestock, Poultry and Dairy (“LPD”), and Other. CAG’s revenues rose 14.6% year over year on a reported basis and 11.6% on an organic basis to $1.05 billion. CAG revenue growth was led by CAG Diagnostics recurring revenue growth of 14% as reported and 11% organic. Veterinary software, services and diagnostic imaging systems revenues grew 12% reportedly and 11% on an organic basis, led by cloud-native software growth and continued installed base expansion, including record diagnostic imaging system installations. The Water segment’s revenues increased 10.9% year over year reportedly and 7.1% on an organic basis to $50.3 million. For the first quarter, LPD revenues jumped 13.6% reportedly and 7.2% on an organic basis to $32.5 million. Revenues from the Other segment dropped 14% on a reported basis as well as organically to $4 million. Gross profit rose 15.9% to $722.7 million. The gross margin expanded 92 basis points (bps) to 63.4% despite an 11.5% rise in the cost of revenues. Sales and marketing expenses surged 12.2% to $175.3 million. G&A expenses rose 30.1% to $119.1 million. R&D expenses jumped 11.4% to $65.8 million. The operating profit in the reported quarter rose 14.5% year over year to $362.6 million. The operating margin in the quarter expanded 8 bps to 31.8%. IDEXX exited the first quarter of 2026 with cash and cash equivalents of $200.5 million compared with $180.1 million at the end of fourth-quarter 2025. Cumulative net cash provided by op...

It's been a good week for IDEXX Laboratories, Inc. (NASDAQ:IDXX) shareholders, because the company has just released its latest quarterly results, and the shares gained 4.6% to US$579. It was a workmanlike result, with revenues of US$1.1b coming in 2.9% ahead of expectations, and statutory earnings per share of US$3.47, in line with analyst appraisals. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Taking into account the latest results, the most recent consensus for IDEXX Laboratories from 14 analysts is for revenues of US$4.70b in 2026. If met, it would imply a satisfactory 5.7% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to accumulate 6.4% to US$14.67. In the lead-up to this report, the analysts had been modelling revenues of US$4.68b and earnings per share (EPS) of US$14.51 in 2026. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results. See our latest analysis for IDEXX Laboratories It will come as no surprise then, to learn that the consensus price target is largely unchanged at US$709. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values IDEXX Laboratories at US$805 per share, while the most bearish prices it at US$470. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable. Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. We can infer from the latest estimates that forecasts expect a continuation of IDEXX Laboratories'historical trends, as the 7.7% annualised revenue growth to the end...

Organic revenue growth of 11% was underpinned by a 12% increase in Companion Animal Group (CAG) revenues, driven by strong diagnostic recurring revenue and premium instrument placements. Management attributed the 1,100 basis point premium over U.S. clinical visit declines to increased diagnostic frequency and higher utilization per visit, reflecting deeper integration of diagnostics into care protocols. The 'aging pet' cohort (pets 5+ years old) is emerging as a resilient growth driver, showing positive clinical visit momentum across both wellness and non-well categories for the third consecutive quarter. International growth of 12% was fueled by long-term investments in commercial expansion and localized software solutions, effectively mitigating similar global macro pressures on veterinary visits. The IDEXX inVue Dx platform is serving as a key growth engine, with 1,100 placements in Q1 supporting a 28% organic increase in instrument revenues and driving new consumable revenue streams. Operating margin expansion of 100 basis points was supported by gross margin gains from high-margin recurring revenue growth and operational productivity, offsetting inflationary pressures. Full-year organic revenue growth guidance was raised to 7.7% to 9.7%, reflecting a 70 basis point increase at the midpoint due to strong global execution and a modestly improved sector outlook. The updated U.S. clinical visit assumption is now a decline of 1.5%, an improvement from previous expectations based on three quarters of consistent trends between -1% and -2%. Management expects a full volume ramp for the Fine Needle Aspirate (FNA) platform in the second half of 2026 as the controlled rollout transitions to an unconstrained launch posture. Q2 2026 guidance assumes a 50 basis point headwind from equivalent days and anticipates a decline in instrument revenues as the company laps significant inVue Dx placements from the prior year. The company maintains a 4% global net price realization target for the full year, with growth primarily expected to be volume-driven through innovation and expanded diagnostic utilization. A $5 million loss on an equity investment in Q1 impacted EPS by $0.05, though this was partially offset by favorable foreign exchange rates and share-based compensation benefits. Supply chain dynamics in the Middle East impacted international growth within the Water bus...

Image source: The Motley Fool. Tuesday, May 5, 2026 at 8:30 a.m. ET Chief Executive Officer — Jay Mazelsky Incoming Chief Executive Officer — Michael Erickson Chief Financial Officer — Andrew Emerson Andrew Emerson: Good morning. I'm pleased to take you through our first quarter results and provide an updated outlook for our full year 2026 financial expectations. During the first quarter, IDEXX delivered exceptional financial results through continued execution in our companion animal business with benefits from IDEXX innovations. Revenue increased 14% as reported and 11% organically supported by over 11% organic growth in CAG Diagnostics recurring revenues, reflecting nearly 11% gains in the U.S. and approximately 12% growth in international regions. CAG Diagnostic recurring revenue growth in Q1 was negatively impacted by declines in U.S. same-store clinical visits of approximately 1%, with slightly positive growth in non-well visits more than offset by pressure on wellness visits. Strong premium instrument placements in the quarter resulted in 28% organic growth of CAG instrument revenues and included 1,100 IDEXX inVue Dx analyzers. IDEXX's operating performance was also excellent with comparable operating margin gains of 100 basis points, supported by gross margin expansion, which benefited from strong reoccurring revenue growth. Strong operating profit gains enabled earnings per share of $3.47 in the quarter, resulting in EPS growth of 15% on a comparable basis. Performance during the first quarter built confidence to increase our full year revenue range to between $4.675 billion to $4.76 billion, an increase of $42 million at midpoint or an outlook for overall reported revenue growth of 8.6% to 10.6%. Our updated full year overall organic revenue growth outlook is for 7.7% to 9.7% with an organic CAG Diagnostic recurring revenue growth of 8.7% to 10.7%. These organic growth ranges represent approximately 70 basis point increase at midpoint to our previous guidance, supported by strong global execution and modest improvement in our sector outlook for the CAG business. We're also updating our full year EPS outlook to $14.45 to $14.90 per share, an increase of $0.13 per share at midpoint net of a $0.05 negative impact from a loss on an equity investment in Q1, reflecting 11% to 15% comparable EPS growth. We'll provide further details on our updated 2026 fi...

Strong Q1 and raised guidance: IDEXX reported Q1 revenue up 14% (11% organic) with EPS of $3.47 (+15% comparable), operating margin up ~100 bps and raised full‑year 2026 revenue to $4.675–$4.76B and EPS to $14.45–$14.90, while free cash flow remained robust ($234M) and net leverage was low (0.5x). Product momentum driving growth: Companion Animal Diagnostics led the quarter—instrument revenue rose 28% organically with 4,650 premium placements (including 1,100 InViewDX units), ongoing InViewDX FNA rollout, growing adoption of Cancer Dx (7,500 practices) and record imaging and cloud‑native software installations. Leadership transition and strategic focus: CEO Jay Mazelsky moves to executive chair and Michael Erickson becomes CEO, prioritizing an innovation‑driven platform across diagnostics, software, commercial expansion and AI, with more AI priorities to be outlined at the August Investor Day. Interested in IDEXX Laboratories, Inc.? Here are five stocks we like better. Bullish or Bearish? Vetting Animal Health Care Stocks IDEXX Laboratories (NASDAQ:IDXX) reported first-quarter 2026 results that management described as an “exceptional start” to the year, driven by continued execution in its companion animal business and contributions from recent innovations. Chief Financial Officer Andrew Emerson said IDEXX’s first-quarter revenue increased 14% as reported and 11% organically. He attributed the performance to “continued execution in our companion animal business with benefits from IDEXX Innovations.” → Roblox Stock Slides to New Low as Safety Changes Weigh on Outlook Emerson highlighted that Companion Animal Group (CAG) Diagnostics recurring revenues grew more than 11% organically, including nearly 11% growth in the U.S. and approximately 12% internationally. He noted, however, that recurring revenue growth faced a headwind from U.S. same-store clinical visits declining about 1% in the quarter. Emerson said slightly positive growth in non-well visits “more than offset” pressure on wellness visits. CAG Diagnostics instrument revenue rose 28% organically, supported by what Emerson called “strong premium instrument placements,” including 1,100 IDEXX InViewDX analyzers. Total CAG premium instrument placements were 4,650 units, up 12% year-over-year, and the premium instrument install base grew 12% year-over-year, according to Emerson. → The Real SpaceX Play: 5 Ch...

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4% and the actively trad

IDEXX Laboratories, Inc. IDXX posted first-quarter 2026 earnings per share (EPS) of $3.47, up 17.2% year over year. The figure surpassed the Zacks Consensus Estimate by 1.5%. Comparable constant-currency EPS of $3.30 improved 15% year over year. Quarterly revenues increased 14% year over year (up 11% organically) to $1.14 billion. The reported figure topped the Zacks Consensus Estimate by 2.1%. Following the earnings announcement, IDXX shares gained 0.3% in the pre-market trading today. IDEXX derives revenues from four operating segments: CAG, Water, Livestock, Poultry andDairy (“LPD”), and Other. CAG’s revenues rose 14.6% year over year on a reported basis and 11.6% on an organic basis to $1.05 billion. CAG revenue growth was led by CAG Diagnostics recurring revenue growth of 14% as reported and 11% organic. Veterinary software, services and diagnostic imaging systems revenues grew 12% reportedly and 11% on an organic basis, led by cloud-native software growth and continued installed base expansion, including record diagnostic imaging system installations. The Water segment’s revenues increased 10.9% year over year reportedly and 7.1% on an organic basis to $50.3 million. For the first quarter, LPD revenues jumped 13.6% reportedly and 7.2% on an organic basis to $32.5 million. Revenues from the Other segment dropped 14% on a reported basis as well as organically to $4 million. Gross profit rose 15.9% to $722.7 million. The gross margin expanded 92 basis points (bps) to 63.4% despite an 11.5% rise in the cost of revenues. Sales and marketing expenses surged 12.2% to $175.3 million. G&A expenses rose 30.1% to $119.1 million. R&D expenses jumped 11.4% to $65.8 million. The operating profit in the reported quarter rose 14.5% year over year to $362.6 million. The operating margin in the quarter expanded 8 bps to 31.8%. IDEXX exited the first quarter of 2026 with cash and cash equivalents of $200.5 million compared with $180.1 million at the end of fourth-quarter 2025. Cumulative net cash provided by operating activities was $266.3 million compared with $238 million in the prior-year period. IDEXX Laboratories, Inc. price-consensus-eps-surprise-chart | IDEXX Laboratories, Inc. Quote IDEXX upgraded an initial outlook for 2026, forecasting revenues in the range of $4,675-$4,760 million (up from $4,632-$4,720 million). The Zacks Consensus Estimate is currently pegge...

Idexx Laboratories (IDXX) came out with quarterly earnings of $3.47 per share, beating the Zacks Consensus Estimate of $3.42 per share. This compares to earnings of $2.96 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +1.50%. A quarter ago, it was expected that this Animal diagnostic and health care company would post earnings of $2.93 per share when it actually produced earnings of $3.08, delivering a surprise of +5.12%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Idexx, which belongs to the Zacks Medical - Instruments industry, posted revenues of $1.14 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 2.10%. This compares to year-ago revenues of $998.43 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Idexx shares have lost about 16.8% since the beginning of the year versus the S&P 500's gain of 5.2%. While Idexx has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Idexx was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Ra...

DENTSPLY SIRONA Inc. XRAY is scheduled to release first-quarter 2026 results on May 5, after market close. In the last reported quarter, the company’s earnings missed the Zacks Consensus Estimate by 3.57%. It delivered an average earnings surprise of 7.73% for the trailing four quarters. The Zacks Consensus Estimate for revenues is pegged at $840.1 million. The consensus mark for earnings is pinned at 28 cents per share. Our model estimates for revenues and adjusted earnings per share (EPS) are pinned at $846.2 million and 32 cents, respectively. DENTSPLY SIRONA’s first-quarter 2026 performance is likely have to reflected continued softness in the United States, along with lingering tariff-related pressures. The company remains in the early phase of executing its multi-year “Return-to-Growth” transformation plan, which is expected to weigh on near-term earnings due to elevated investments in innovation, commercial reorganization and clinical education. While these actions are aimed at restoring sustainable growth, they are likely to have kept margins under pressure in the to-be-reported quarter. Tariffs and softer demand trends in key categories like equipment, implants and CAD/CAM solutions are expected to continue in the U.S. market. Management also highlighted a headwind from dealer inventory adjustments, particularly tied to a shift toward a drop-ship model, with roughly $30 million of inventory expected to be worked down in the first half of 2026. These dynamics are likely to have weighed on volumes and revenue visibility in the quarter to be reported. From a segmental standpoint, ongoing weakness in Connected Technology Solutions, implants and orthodontics is likely to have persisted, given competitive pressures and lower procedural volumes. However, relatively stable trends in Essential Dental Solutions, along with continued strength in Wellspect Healthcare, may have provided some support. Distributor inventory levels for equipment and CAD/CAM remained below historical averages exiting 2025, indicating that any recovery is likely to be gradual and dependent on dealer reengagement efforts. On the geographic front, while the U.S. business is expected to have remained under pressure, international markets — particularly Europe — likely continued to demonstrate resilience. Management previously indicated stable end-market conditions outside the United Sta...

Idexx Laboratories (IDXX) reported $1.14 billion in revenue for the quarter ended March 2026, representing a year-over-year increase of 14.3%. EPS of $3.47 for the same period compares to $2.96 a year ago. The reported revenue represents a surprise of +2.1% over the Zacks Consensus Estimate of $1.12 billion. With the consensus EPS estimate being $3.42, the EPS surprise was +1.5%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Idexx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Percent of Revenue- Gross Profit - CAG: 63.3% compared to the 61.8% average estimate based on three analysts. Percent of Revenue- Gross Profit - LPD: 52.1% compared to the 49.7% average estimate based on three analysts. Percent of Revenue- Gross Profit - Water: 72.7% versus 70% estimated by three analysts on average. Revenue- Companion Animal Group(CAG)- United States: $690.9 million versus $687.86 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +10.7% change. Revenue- Companion Animal Group(CAG)- International: $363.15 million compared to the $352.35 million average estimate based on two analysts. The reported number represents a change of +22.7% year over year. Revenue- LPD- International: $26.1 million versus $25.14 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +14.4% change. Revenue- Water- International: $23.87 million compared to the $25.48 million average estimate based on two analysts. The reported number represents a change of +9.4% year over year. Revenue- Companion Animal Group (CAG): $1.05 billion versus $1.03 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +14.6% change. Revenue- Other: $4.02 million compared to the $4.62 million average estimate based on five ana...